Literature DB >> 30694569

Loss of RHBDF2 results in an early-onset spontaneous murine colitis.

Ramasatyaveni Geesala1,2, Willow Schanz1,2, Mikayla Biggs1,2, Garima Dixit1,2, Joseph Skurski1,2,3, Prajwal Gurung1,2,3, David K Meyerholz4, David Elliott5, Priya D Issuree1,2, Thorsten Maretzky1,2,3,6.   

Abstract

Inflammatory bowel disease (IBD) is a heterogeneous group of inflammation-mediated pathologies that include Crohn's disease and ulcerative colitis and primarily affects the colon and small intestine. Previous studies have shown that a disintegrin and metalloprotease (ADAM) 17, a membrane-bound sheddase, capable of cleaving the proinflammatory cytokine TNF and epidermal growth factor receptor ligands, plays a critical role in maintaining gut homeostasis and modulating intestinal inflammation during IBD. Rhomboid 5 homolog 2 (RHBDF2), a catalytically inactive member of the rhomboid family of intramembrane serine proteases, was recently identified as a crucial regulator of ADAM17. Here, we assessed the role of RHBDF2 in the development of colitis in the context of IL10 deficiency. Il10-/- /Rhbdf2-/- mice developed spontaneous colitis and experienced severe weight loss starting at 8 wk of age, without the need for exogenous triggers. Severity of disease pathology in Il10-/- /Rhbdf2-/- mice correlated with a dysbiotic gut microbiota and elevated Th1-associated immune responses with increased interferon gamma and IL2 production. In addition, Il10-/- /Rhbdf2-/- mice failed to maintain their epithelial cell homeostasis, although the intestinal epithelial barrier of Rhbdf2-/- mice is intact and loss of Rhbdf2 did not significantly exacerbate sensitivity to dextran sulfate sodium-induced colitis, suggesting differences in the underlying disease pathway of intestinal inflammation in this model. Taken together, our results demonstrate a critical regulatory role for RHBDF2 in the maintenance of the unique homeostasis between intestinal microbiota and host immune responses in the gut that is dysregulated during the pathogenesis of IBD. ©2019 Society for Leukocyte Biology.

Entities:  

Keywords:  Inflammatory bowel disease (IBD); a disintegrin and metalloprotease (ADAM) 17; epidermal growth factor receptor (EGFR); inactive rhomboid iRhom2; rhomboid 5 homolog 2 (RHBDF2)

Mesh:

Substances:

Year:  2019        PMID: 30694569      PMCID: PMC6585405          DOI: 10.1002/JLB.4A0718-283RR

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  65 in total

Review 1.  ADAMs: key components in EGFR signalling and development.

Authors:  Carl P Blobel
Journal:  Nat Rev Mol Cell Biol       Date:  2005-01       Impact factor: 94.444

2.  A widely applicable protocol for DNA isolation from fecal samples.

Authors:  Bao-Wei Zhang; Ming Li; Li-Chao Ma; Fu-Wen Wei
Journal:  Biochem Genet       Date:  2006-12       Impact factor: 1.890

3.  Alterations in intestinal fatty acid metabolism in inflammatory bowel disease.

Authors:  Susanne Heimerl; Christoph Moehle; Alexandra Zahn; Alfred Boettcher; Wolfgang Stremmel; Thomas Langmann; Gerd Schmitz
Journal:  Biochim Biophys Acta       Date:  2006-01-05

4.  Analysis of the fecal microbiota of irritable bowel syndrome patients and healthy controls with real-time PCR.

Authors:  Erja Malinen; Teemu Rinttilä; Kajsa Kajander; Jaana Mättö; Anna Kassinen; Lotta Krogius; Maria Saarela; Riitta Korpela; Airi Palva
Journal:  Am J Gastroenterol       Date:  2005-02       Impact factor: 10.864

5.  A simple method for assessing intestinal inflammation in Crohn's disease.

Authors:  J Tibble; K Teahon; B Thjodleifsson; A Roseth; G Sigthorsson; S Bridger; R Foster; R Sherwood; M Fagerhol; I Bjarnason
Journal:  Gut       Date:  2000-10       Impact factor: 23.059

6.  Inflammatory bowel disease is associated with a TNF polymorphism that affects an interaction between the OCT1 and NF(-kappa)B transcription factors.

Authors:  David A van Heel; Irina A Udalova; Arjuna P De Silva; Dermot P McGovern; Yoshitaka Kinouchi; Jeremy Hull; Nicholas J Lench; Lon R Cardon; Alisoun H Carey; Derek P Jewell; Dominic Kwiatkowski
Journal:  Hum Mol Genet       Date:  2002-05-15       Impact factor: 6.150

Review 7.  Structure-function and biological role of betacellulin.

Authors:  A J Dunbar; C Goddard
Journal:  Int J Biochem Cell Biol       Date:  2000-08       Impact factor: 5.085

8.  Tumour necrosis factor alpha converting enzyme (TACE) activity in the colonic mucosa of patients with inflammatory bowel disease.

Authors:  J Brynskov; P Foegh; G Pedersen; C Ellervik; T Kirkegaard; A Bingham; T Saermark
Journal:  Gut       Date:  2002-07       Impact factor: 23.059

9.  TNF-alpha is a critical negative regulator of type 1 immune activation during intracellular bacterial infection.

Authors:  Anna Zganiacz; Michael Santosuosso; Jun Wang; Tony Yang; Lihao Chen; Maria Anzulovic; Scott Alexander; Brigitte Gicquel; Yonghong Wan; Jonathan Bramson; Mark Inman; Zhou Xing
Journal:  J Clin Invest       Date:  2004-02       Impact factor: 14.808

10.  Validation of the interleukin-10 knockout mouse model of colitis: antitumour necrosis factor-antibodies suppress the progression of colitis.

Authors:  T Scheinin; D M Butler; F Salway; B Scallon; M Feldmann
Journal:  Clin Exp Immunol       Date:  2003-07       Impact factor: 4.330

View more
  10 in total

1.  Sex-specific differences in cardiac function, inflammation and injury during early polymicrobial sepsis.

Authors:  Sophie L M Walker; Chand Muthoo; Jenifer Sanchez; Ana Gutierrez Del Arroyo; Gareth L Ackland
Journal:  Intensive Care Med Exp       Date:  2022-06-20

Review 2.  Role of ErbB1 in the Underlying Mechanism of Lapatinib-Induced Diarrhoea: A Review.

Authors:  Raja Nur Firzanah Syaza Raja Sharin; Jesmine Khan; Mohamad Johari Ibahim; Mudiana Muhamad; Joanne Bowen; Wan Nor I'zzah Wan Mohamad Zain
Journal:  Biomed Res Int       Date:  2022-06-28       Impact factor: 3.246

Review 3.  Pathway paradigms revealed from the genetics of inflammatory bowel disease.

Authors:  Daniel B Graham; Ramnik J Xavier
Journal:  Nature       Date:  2020-02-26       Impact factor: 49.962

Review 4.  Cross Talk between Gut Microbiota and Intestinal Mucosal Immunity in the Development of Ulcerative Colitis.

Authors:  Junfeng Zou; Chen Liu; Shu Jiang; Dawei Qian; Jinao Duan
Journal:  Infect Immun       Date:  2021-08-16       Impact factor: 3.441

5.  A highly polarized TH2 bladder response to infection promotes epithelial repair at the expense of preventing new infections.

Authors:  Jianxuan Wu; Byron W Hayes; Cassandra Phoenix; Gustavo Sosa Macias; Yuxuan Miao; Hae Woong Choi; Francis M Hughes; J Todd Purves; R Lee Reinhardt; Soman N Abraham
Journal:  Nat Immunol       Date:  2020-05-18       Impact factor: 25.606

6.  The Threshold Effect: Lipopolysaccharide-Induced Inflammatory Responses in Primary Macrophages Are Differentially Regulated in an iRhom2-Dependent Manner.

Authors:  Joseph Skurski; Garima Dixit; Carl P Blobel; Priya D Issuree; Thorsten Maretzky
Journal:  Front Cell Infect Microbiol       Date:  2021-01-29       Impact factor: 5.293

Review 7.  Strategies to Target ADAM17 in Disease: From its Discovery to the iRhom Revolution.

Authors:  Matteo Calligaris; Doretta Cuffaro; Simone Bonelli; Donatella Pia Spanò; Armando Rossello; Elisa Nuti; Simone Dario Scilabra
Journal:  Molecules       Date:  2021-02-10       Impact factor: 4.411

Review 8.  The Role of iRhom2 in Metabolic and Cardiovascular-Related Disorders.

Authors:  Ramasatyaveni Geesala; Priya D Issuree; Thorsten Maretzky
Journal:  Front Cardiovasc Med       Date:  2020-11-24

9.  Inflammatory activation of surface molecule shedding by upregulation of the pseudoprotease iRhom2 in colon epithelial cells.

Authors:  Anja Adelina Giese; Aaron Babendreyer; Stefan Düsterhöft; Andreas Ludwig; Peter Krappen; Annika Gross; Pavel Strnad
Journal:  Sci Rep       Date:  2021-12-20       Impact factor: 4.379

Review 10.  iRhom2: An Emerging Adaptor Regulating Immunity and Disease.

Authors:  Mazin A Al-Salihi; Philipp A Lang
Journal:  Int J Mol Sci       Date:  2020-09-08       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.